Beta Pharma

Executive Summary

Beta Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in Princeton, New Jersey, established in 2007 with a focus on discovering, developing, and commercializing innovative small-molecule oncology therapies. The company's mission is to make advanced anticancer treatments accessible while improving patient quality of life. Its pipeline targets major solid tumors, including non-small cell lung cancer (NSCLC), metastatic breast cancer, and other solid tumors, with a particular emphasis on late-stage development. Leveraging its expertise in targeted small molecules, Beta Pharma aims to address high unmet needs in oncology through a portfolio of therapies that combine novel mechanisms with favorable safety profiles. As a private entity, the company has maintained a low public profile but has been recognized in industry listings for its promising pipeline and strategic location in the Princeton biotech hub. Beta Pharma's development strategy appears centered on advancing candidates through clinical trials toward regulatory approval and commercialization. While specific pipeline details are not publicly available, the company's focus on late-stage oncology suggests proximity to key milestones such as data readouts, regulatory submissions, or partnership agreements. The company's ability to attract collaborators and secure funding will be critical to its progression. Given the competitive oncology landscape, Beta Pharma's differentiation likely hinges on the efficacy and tolerability of its targeted therapies. With a dedicated team and a clear mission, the company is poised to contribute meaningfully to cancer treatment, though its success remains contingent on clinical outcomes and strategic execution.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead NSCLC candidate60% success
• TBDPartnership agreement for metastatic breast cancer asset45% success
• H1 2027IND filing for next-generation solid tumor therapy70% success